Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002369650 | SCV002664969 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2020-03-26 | criteria provided, single submitter | clinical testing | The c.683+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 5 in the SUFU gene. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to weaken the efficiency of the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |